Cocrystal Pharma Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
10
- Stock Symbol
-
COCP
- Investments
-
2
- Share Price
-
$1.01
- (As of Tuesday Closing)
Cocrystal Pharma General Information
Description
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Contact Information
Website
www.cocrystalpharma.comCorporate Office
- 19805 North Creek Parkway
- Bothell, WA 98011
- United States
Corporate Office
- 19805 North Creek Parkway
- Bothell, WA 98011
- United States
Cocrystal Pharma Timeline
Cocrystal Pharma Stock Performance
As of 17-Nov-2026, Cocrystal Pharma’s stock price is $1.01. Its current market cap is $19.5M with 19.3M shares.
(As of Tuesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.01 | $0.98 | $0.76 - $2.03 | $19.5M | 19.3M | 44.9K | -$0.76 |
Cocrystal Pharma Financials Summary
As of 30-Sep-2026, Cocrystal Pharma has a trailing 12-month revenue of $435K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 21,325 | 7,349 | 9,406 | (12,099) |
| Revenue | 435 | 0 | 0 | 0 |
| EBITDA | (11,060) | (8,589) | (17,595) | (18,624) |
| Net Income | (11,333) | (8,831) | (17,504) | (17,984) |
| Total Assets | 6,773 | 9,712 | 13,456 | 31,259 |
| Total Debt | 1,257 | 1,505 | 1,806 | 1,853 |
Cocrystal Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cocrystal Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Cocrystal Pharma Comparisons
Industry
Financing
Details
Cocrystal Pharma Competitors (60)
One of Cocrystal Pharma’s 60 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Marengo Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Sorrento Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Immunocore Holdings | Formerly VC-backed | Abingdon, United Kingdom |
Cocrystal Pharma Patents
Cocrystal Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4384178-A1 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | Pending | 11-Aug-2021 | ||
| EP-4384178-A4 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | Pending | 11-Aug-2021 | ||
| US-20250230161-A1 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | Pending | 11-Aug-2021 | ||
| WO-2023018913-A1 | Polycyclic cap-dependent endonuclease inhibitors for treating or preventing influenza | Inactive | 11-Aug-2021 | ||
| JP-2024530920-A | Inhibitors against coronaviruses | Pending | 03-Aug-2021 | A61K31/4015 |
Cocrystal Pharma Signals
Cocrystal Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cocrystal Pharma Acquisitions (2)
Cocrystal Pharma’s most recent deal was a Merger/Acquisition with RFS Pharma for . The deal was made on 25-Nov-2014.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| RFS Pharma | 25-Nov-2014 | Merger/Acquisition | Drug Discovery | ||
| Biozone Pharmaceuticals | 02-Jan-2014 | Merger/Acquisition | Personal Products |
Cocrystal Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Cocrystal Pharma FAQs
-
When was Cocrystal Pharma founded?
Cocrystal Pharma was founded in 2008.
-
Where is Cocrystal Pharma headquartered?
Cocrystal Pharma is headquartered in Bothell, WA.
-
What is the size of Cocrystal Pharma?
Cocrystal Pharma has 10 total employees.
-
What industry is Cocrystal Pharma in?
Cocrystal Pharma’s primary industry is Drug Discovery.
-
Is Cocrystal Pharma a private or public company?
Cocrystal Pharma is a Public company.
-
What is Cocrystal Pharma’s stock symbol?
The ticker symbol for Cocrystal Pharma is COCP.
-
What is the current stock price of Cocrystal Pharma?
As of 17-Nov-2026 the stock price of Cocrystal Pharma is $1.01.
-
What is the current market cap of Cocrystal Pharma?
The current market capitalization of Cocrystal Pharma is $19.5M.
-
What is Cocrystal Pharma’s current revenue?
The trailing twelve month revenue for Cocrystal Pharma is $435K.
-
Who are Cocrystal Pharma’s competitors?
Marengo Therapeutics, Adaptimmune Therapeutics, Altimmune, Sorrento Therapeutics, and Immunocore Holdings are some of the 60 competitors of Cocrystal Pharma.
-
What is Cocrystal Pharma’s annual earnings per share (EPS)?
Cocrystal Pharma’s EPS for 12 months was -$0.76.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process